AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05331911
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: total intravenous anesthesia with propofol for the partial hepatectomy of hepatocellular carcinoma.
Trial: NCT05331911
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3 MAC).
Trial: NCT00002254
Drug: Alovudine
RxNorm normalized name: Alovudine
DrugBank: Alovudine (DB06198)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05117021
Drug: Caudal Epidural Block using 0.25% plain bupivacaine dose 1 ml / kg and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine dose 0.5 ml / kg
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caudal Epidural Block and Ultrasound Guided Transversus Abdominis Plane Block using 0.25% plain bupivacaine
Trial: NCT05768243
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hyaluronic acid is used as an adjunctive treatment to scaling and root planing
Trial: NCT04460586
Drug: Omadacycline Injection [Nuzyra]
RxNorm normalized name: omadacycline Injection [Nuzyra]
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
Trial: NCT04460586
Drug: Omadacycline Oral Tablet [Nuzyra]
RxNorm normalized name: omadacycline Oral Tablet [Nuzyra]
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of omadacycline 100mg IV followed by a 1-week washout and receipt of single dose omadacycline 300 mg PO.
Trial: NCT05229796
Drug: Empagliflozin 10 mg Tab
RxNorm normalized name: empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The Empagliflozin 10 mg Tab were administered orally. The plasma concentrations of empagliflozin were determined using an HPLC-MS/MS method. Tolerability and safety were assessed throughout the study. This study included 26 subjects, 26 in each fasting and fed group.
Trial: NCT05065567
Drug: Droperidol
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV
Trial: NCT05065567
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM
Trial: NCT05065567
Drug: Ondansetron 8mg
RxNorm normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
Trial: NCT04754230
Drug: Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)
RxNorm normalized name: tranexamic acid 1,000 mg/10 mL (100 mg/mL) INTRAVEN VIAL (ML)
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication administered 15 minutes prior to end of surgery.
Trial: NCT05473286
Drug: Oral Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Trial: NCT05729139
Drug: Cemiplimab-Rwlc
RxNorm normalized name: cemiplimab-rwlc
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 350 mg via IV infusion over 30 minutes every 3 weeks for up to two years
Trial: NCT05729139
Drug: PEG-IFN alfa-2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established.
Trial: NCT04958746
Drug: Ciprofol
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous bolus
Trial: NCT04958746
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous bolus
Trial: NCT00002077
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05054543
Drug: Uproleselan
RxNorm normalized name: Uproleselan
DrugBank: Uproleselan (DB14829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
Trial: NCT05458856
Drug: Triptorelin embonate 22.5 mg
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
Trial: NCT05334277
Drug: Furmonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furmonertinib 80mg QD
Trial: NCT05334277
Drug: Furmonertinib/Pemetrexed/Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.
Trial: NCT05334277
Drug: Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
Trial: NCT04148092
Drug: ripretinib
RxNorm normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: orally administered solid dosage form
Trial: NCT05013268
Drug: Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Drug: Tislelizumab 200mg, d1, ivgtt, every 3 weeks, for 3 cycles~* Drug: Paclitaxel; docetaxel Dose: 175mg/m2 d1; 75mg/m2 d1, every 3 weeks, for 3 cycles Other Name: none~* Drug: Cisplatin; Carboplatin Dose: 75mg/m2 d1; AUC=5, d1, every 3 weeks, for 3 cycles Other Name: none
Trial: NCT04558931
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Naked immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds to the human cell surface antigen molecule classified as cluster of differentiation (CD) 38
Trial: NCT04927793
Drug: EDP-938
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]EDP-938
Trial: NCT05440136
Drug: LY3462817 (SC)
RxNorm normalized name: Immunoglobulin g1, anti-(human programmed cell death protein 1) (human monoclonal ly3462817 .gamma.1-chain), disulfide with human monoclonal ly3462817 .kappa.-chain, dimer
DrugBank: Peresolimab (DB18874)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05440136
Drug: LY3462817 (IV)
RxNorm normalized name: Immunoglobulin g1, anti-(human programmed cell death protein 1) (human monoclonal ly3462817 .gamma.1-chain), disulfide with human monoclonal ly3462817 .kappa.-chain, dimer
DrugBank: Peresolimab (DB18874)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT06427694
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL2 antagonist
Trial: NCT06427694
Drug: Dextrose 5% in water
RxNorm normalized name: LVP solution Dextrose 5% in Water intravenous solution
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo to active
Trial: NCT04794790
Drug: Buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine/Naloxone induction via a standard dose protocol
Trial: NCT05165212
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 10% of a standard weight-based dose of amoxicillin and observed for signs/symptoms of allergic reaction for 30 minutes. If no reaction occurs, they will given the remaining 90% of the standard dose and observed for an additional 30 minutes.
Trial: NCT05834517
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic Acid (HA) is an addition to the local chemotherapeutic agents. Hyaluronic acid was discovered by Meyer and Palmer. HA is widely found in the extracellular matrix and it plays an essential role in controlling cell behavior including random motility, metabolic reactions, chemotaxis, proliferation and invasion. HA is released by many cells including fibroblasts
Trial: NCT06202781
Drug: SOX plus PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1, Oxaliplatin and nivolumab/sintilimab
Trial: NCT04946617
Drug: undefined
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rinsing with mouthwashes
Trial: NCT04924829
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.
Trial: NCT05352828
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose: 480 mg or 6 mg/kg Q4W
Trial: NCT05352828
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 30 mg/m2/day x 3 days
Trial: NCT05352828
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 70 mg/m2/day x 3 days
Trial: NCT00324831
Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00324831
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00324831
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00324831
Drug: sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00324831
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04738773
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.
Trial: NCT06224842
Drug: mitoxantrone liposome 16 and azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
Trial: NCT06224842
Drug: mitoxantrone liposome 18 and azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
Trial: NCT06224842
Drug: mitoxantrone liposome 20 and azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
Trial: NCT04100434
Drug: Evolocumab
RxNorm normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
Trial: NCT04973345
Drug: Terbutaline
RxNorm normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: management of asthma symptoms
Trial: NCT05279586
Drug: lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: all interventions are used in secondary prophylaxis in cirrhotic patients
Trial: NCT05279586
Drug: colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all interventions are used in secondary prophylaxis in cirrhotic patients
Trial: NCT05883904
Drug: Fedratinib
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib administered after AIFA reimbusement approval
Trial: NCT06390787
Drug: Metoclopramide and Vitamin B6
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.
Trial: NCT06390787
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.
Trial: NCT06390787
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We gave only Zofran as a treatment for managing nausea and vomiting.
Trial: NCT06390787
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We gave only Metoclopramide as a treatment for managing nausea and vomiting.
Trial: NCT06076694
Drug: TNP-2198
RxNorm normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days
Trial: NCT06076694
Drug: Rabeprazole Sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
Trial: NCT06076694
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
Trial: NCT05905484
Drug: Bemnifosbuvir (BEM)
RxNorm normalized name: Bemnifosbuvir
DrugBank: Bemnifosbuvir (DB19050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of BEM will be administered.
Trial: NCT05905484
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of Moxifloxacin will be administered.
Trial: NCT04064346
Drug: Lixivaptan
RxNorm normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vasopressin V2 receptor antagonist
Trial: NCT05760534
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.075 mg/kg Remimazolam will be loaded over 1 min, then continuously infused at 0.2-1.0 mg/kg/h based on ideal or total body weight
Trial: NCT04784533
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Oral dosing
Trial: NCT05978102
Drug: STI-7349
RxNorm normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion (IV)
Trial: NCT05978102
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intravenous infusion (IV)
Trial: NCT06172920
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are receiving tramadol hydrochloride under thoracic surgery
Trial: NCT06172920
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are receiving Morphine hydrochloride under thoracic surgery
Trial: NCT06116695
Drug: human treated dentin matrix
RxNorm normalized name: Matrix
DrugBank: Matrix-M (DB16369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
Trial: NCT06116695
Drug: Mineral Tri-Oxide Aggregate
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mineral trioxide aggregate was used as control
Trial: NCT05677620
Drug: Drug-Induced Sleep Endoscopy (Propofol)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
Trial: NCT04906785
Drug: CKD-385
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Drug
Trial: NCT04906785
Drug: D744
RxNorm normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference Drug
Trial: NCT06151236
Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
Trial: NCT06255652
Drug: Cephradin
RxNorm normalized name: Cephradin
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Velosef
Trial: NCT05159245
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ALK
Trial: NCT05159245
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MEK1, MEK2
Trial: NCT05159245
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hedgehog
Trial: NCT05159245
Drug: Trastuzumab+Pertuzumab
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HER2
Trial: NCT05159245
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NTRK/ ROS1, ALK
Trial: NCT05159245
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD-L1
Trial: NCT05159245
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BRAF V600
Trial: NCT05159245
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: KIT/BRAF, RET
Trial: NCT00225342
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00225342
Drug: Gliclazide (Comparison drug)
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05159245
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AR
Trial: NCT05159245
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK4/6